WU-CART-007
wugen,spdr s&p biotech,ishares biotechnology
['$ibb', '$xbi', 'wugen']
wugen's first-in-human phase 1/2 trial of wu-cart-007 shows promising initial data at eha 2023 congress for potential breakthrough cancer treatment. more info: $xbi $ibb $xph $pph 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt